You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Phase 3, Follicular Lymphoma, FL, PI3K

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Follicular Lymphoma Trial in Germany (Copanlisib, Obinutuzumab)

Recruiting
  • Follicular Lymphoma
  • München, Bavaria, Germany
  • +39 more
May 19, 2022

MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Atlanta, Columbus (drug, biological,

Completed
  • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
  • +8 more
  • PI3K inhibitor BKM120
  • +3 more
  • Atlanta, Georgia
  • +1 more
Jun 27, 2022

Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL) Trial (parsaclisib, rituximab, obinutuzumab)

Withdrawn
  • Follicular Lymphoma ( FL)
  • Marginal Zone Lymphoma (MZL)
  • (no location specified)
Jul 14, 2022

Follicular Lymphoma, Endometrial Cancer Trial in New York (Copanlisib, Ketogenic Diet)

Recruiting
  • Follicular Lymphoma
  • Endometrial Cancer
  • New York, New York
  • +2 more
Nov 24, 2021

Follicular Lymphoma (FL) Trial in Noblesville (Odronextamab, Rituximab, Cyclophosphamide)

Recruiting
  • Follicular Lymphoma (FL)
  • Noblesville, Indiana
    Investigative Clinical Research of Indiana
Oct 18, 2023

Follicular Lymphoma (FL) Trial in Westbury (Odronextamab, Rituximab, Cyclophosphamide)

Recruiting
  • Follicular Lymphoma (FL)
  • Westbury, New York
    Clinical Research Alliance Inc
Oct 13, 2023

Indolent Non-hodgkin Lymphoma Trial in Shanghai (IBI376)

Active, not recruiting
  • Indolent Non-hodgkin Lymphoma
  • Shanghai, China
    Ruijin hospital, school of medicine, Shanghai jiao tong universi
Oct 3, 2022

Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Duarte (Tazemetostat, Ublituximab, Umbralisib)

Not yet recruiting
  • Recurrent Follicular Lymphoma
  • Refractory Follicular Lymphoma
  • Duarte, California
    City of Hope Medical Center
Jul 31, 2022

Follicular Lymphoma Trial in Duarte, Irvine (procedure, other, biological, drug)

Not yet recruiting
  • Follicular Lymphoma
  • Biospecimen Collection
  • +7 more
  • Duarte, California
  • +1 more
Oct 27, 2023

Follicular Lymphoma, Low Grade Non-Hodgkin's Lymphoma, Adult Trial in Boston (Epcoritamab, Rituximab)

Not yet recruiting
  • Follicular Lymphoma
  • Low Grade Non-Hodgkin's Lymphoma, Adult
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Mar 13, 2023

Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma (MZL) Trial in Chiang Mai (Odronextamab, Lenalidomide,

Recruiting
  • Relapsed/Refractory Follicular Lymphoma
  • Marginal Zone Lymphoma (MZL)
  • Chiang Mai, Thailand
    Chiang Mai University
Nov 20, 2023

Inert Non Hodgkin's Lymphoma Trial in Beijing (IBI376, Rituximab)

Recruiting
  • Inert Non Hodgkin's Lymphoma
  • Beijing, China
    Biotherapeutic Department, Chinese PLA General Hospital
Feb 19, 2022

Endometrial Cancer, Ovarian Cancer Trial in Houston (Copanlisib, fulvestrant)

Recruiting
  • Endometrial Cancer
  • Ovarian Cancer
  • Houston, Texas
    M D Anderson Cancer Center
Sep 27, 2022

Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann

Active, not recruiting
  • Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma
  • +11 more
  • Washington, District of Columbia
  • +6 more
Feb 2, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Follicular Lymphoma Trial in Australia, China (BGB-10188,

Recruiting
  • Chronic Lymphocytic Leukemia
  • +9 more
  • Adelaide, Australia
  • +12 more
Jan 6, 2023

Relapsed/Refractory Marginal Zone Lymphoma Trial in Westbury (Zanubrutinib, Rituximab, Lenalidomide)

Recruiting
  • Relapsed/Refractory Follicular Lymphoma
  • Marginal Zone Lymphoma
  • Westbury, New York
    Clinical Research Alliance, Inc.
Nov 14, 2022

Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma Trial in

Recruiting
  • Ann Arbor Stage II Follicular Lymphoma
  • +5 more
  • Fresno, California
  • +2 more
Jan 24, 2023

Lymphoma, Small Lymphocytic, Lymphoma, Lymphoma, Non-Hodgkin Trial in United States (duvelisib, PI3K inhibitor)

Terminated
  • Lymphoma, Small Lymphocytic
  • +4 more
  • Little Rock, Arkansas
  • +10 more
Mar 15, 2021

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma Trial in United States (TGR-1202, Ibrutinib)

Active, not recruiting
Has Results
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Mantle Cell Lymphoma
  • Monterey, California
  • +4 more
Aug 29, 2022

Metastatic Breast Cancer Trial in East Melbourne (BYl719)

Completed
  • Metastatic Breast Cancer
  • East Melbourne, Victoria, Australia
    Peter MacCallum Cancer Centre
Aug 11, 2022

Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,

Completed
  • Grade 3a Follicular Lymphoma
  • +9 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 31, 2023

Follicular Lymphoma Trial in Toronto (12 Gy in 6 daily fractions)

Recruiting
  • Follicular Lymphoma
  • 12 Gy in 6 daily fractions
  • Toronto, Ontario, Canada
    Sunnybrook Health Sciences Centre
Mar 10, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma Trial in

Suspended
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Jan 20, 2023

Chronic Lymphocytic Leukemia, DLBCL, Follicular Lymphoma Trial in Duarte, Boston, Portland (Copanlisib, Nivolumab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • +6 more
  • Duarte, California
  • +2 more
Mar 9, 2022

Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,

Not yet recruiting
  • Non-hodgkin Lymphoma
  • +9 more
  • CD79b-19 CAR T cells
  • +2 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Sep 6, 2023